Pancreatic cancer news: October 2026 brings new research and a clearer call for access
October’s news included important cancer-vaccine results, new clues about treatment resistance, and Canadian developments in genetic testing and access. Here is what the findings could mean for patients and families—and what remains experimental.
October brought meaningful pancreatic cancer news, but not all of it means the same thing for patients.
A major vaccine study reported its main results. Researchers also published new work on why pancreatic cancer can resist treatment and why involuntary weight loss can begin so early. In Canada, British Columbia clarified who should receive hereditary genetic testing, while a Vancouver patient's experience showed how difficult it can be to obtain a promising medicine that is not yet approved here.
The Heather Cutler Foundation also published its national report, Where You Live Matters: How Canada Responds to Pancreatic Cancer, in October. The report examines how well health systems across Canada are organized to support people facing this disease.
Here is what happened, what the evidence actually shows and what it could mean for patients and families.
The access gap became personal
CBC reported on October 26 that Vancouver resident James Howard has been paying approximately $90,000 a month to obtain daraxonrasib from the United States.
Daraxonrasib is an experimental RAS inhibitor that has produced encouraging results in clinical research. As of CBC's October report, daraxonrasib was not approved in Canada, and the manufacturer had not then applied for Canadian approval.
The $90,000 figure describes Howard's individual experience obtaining the drug across the border. It should not be understood as an official Canadian price or as the amount every patient would pay. Even so, his experience draws attention to a wider problem: a treatment can generate international headlines while remaining practically unavailable to Canadians who do not have exceptional personal resources or another route of access.
What this means for patients
Patients who read about a promising medicine should ask their cancer team:
- Is this treatment approved in Canada?
- Is a clinical trial available?
- Could it be obtained through a special access or compassionate-use process?
- What would the medicine, travel, monitoring and related care cost?
- How strong is the evidence for someone in my situation?
CBC reported that Howard's clinicians have also been looking for clinical-trial or compassionate-access routes for other patients. That does not guarantee that those routes will be available, but it shows why patients should not assume that paying privately in another country is the only possibility.
The vaccine study: encouraging immune responses, but its main goal was not met
Results from the phase 2 AMPLIFY-7P study of camupepimut, also called ELI-002 7P, were published in Nature Medicine on October 23.
Camupepimut is a therapeutic cancer vaccine. It is intended to train a patient's immune system to recognize abnormal KRAS proteins found in many pancreatic cancers. The study involved people whose pancreatic cancer had been removed surgically and who had also received chemotherapy. Some participants had no detectable cancer on scans but still had blood markers suggesting that a small amount of disease could remain.
The study included 144 people with pancreatic or colorectal cancer. Its main question was whether vaccination improved recurrence-free survival, meaning the length of time before cancer returned or a participant died.
The vaccine did not clearly meet that main goal. Overall, the study did not establish that camupepimut lengthened the time before recurrence.
That result matters. It would be misleading to describe AMPLIFY-7P simply as a breakthrough.
At the same time, the study produced information that researchers consider worth pursuing:
- Nearly all participants who could be assessed developed immune responses directed against KRAS.
- Some developed broader immune responses against additional tumour targets.
- Exploratory analyses raised questions about whether smaller groups of patients, including some whose circulating tumour DNA had become undetectable after earlier treatment, might respond differently.
Those additional findings do not prove that the vaccine helped those patients live longer or remain cancer-free. Smaller subgroup findings can occur by chance and need to be tested in a study designed specifically to answer that question.
Read the AMPLIFY-7P results in Nature Medicine
What this means for patients
Camupepimut remains experimental. It is not a standard treatment in Canada, and these results do not show that it prevents recurrence.
The study does show that researchers can generate measurable immune responses against KRAS in most treated patients. That is scientifically important, but an immune response in a blood test is not the same as proof that a treatment controls cancer.
Talk with your cancer team about whether a clinical trial is appropriate and whether any study is available to you. The results support further research, not a change in standard care today.
Why one pancreatic tumour can contain several kinds of cancer cells
A study published in Nature Genetics on October 13 examined why pancreatic cancers can behave so differently, even within the same tumour.
Researchers analysed more than 443,000 individual cells from 62 pancreatic tumours. They found that a tumour is not made up of one uniform type of cancer cell. As the cancer evolves, groups of cells can acquire different genetic changes and develop different behaviours.
The researchers paid particular attention to MYC, a gene that helps control cell growth. In tumours with extra copies of MYC, they found a more aggressive group of cancer cells. These cells were less like normal pancreatic duct cells, showed features associated with invasion and were less visible to the immune system.
In laboratory research using mouse and human cancer models, reducing MYC activity changed the behaviour of the aggressive cells. They began to resemble a less aggressive form of pancreatic cancer and showed features that could make them easier for the immune system to recognize.
Read the clonal-heterogeneity study in Nature Genetics
What this means for patients
This is laboratory research, not a new treatment.
No patient in this study received a MYC-targeting medicine, and MYC has historically been very difficult to target directly with drugs. It would therefore be wrong to say that scientists have found a way to switch pancreatic cancer from an aggressive form into a treatable one in people.
The work is still valuable because it helps explain treatment resistance. If a tumour contains several different populations of cells, a treatment may eliminate some of them while leaving the more aggressive cells behind. Understanding how those cells develop could help researchers design treatments that address more than one population at a time.
For now, this research mainly changes what scientists investigate next.
Weight loss may begin earlier than many people realize
An international group of researchers published a large study of cancer cachexia in Nature Medicine on October 12.
Cachexia is more than ordinary weight loss. It is a wasting syndrome involving loss of weight, muscle and strength that cannot be fully reversed simply by eating more. It can affect treatment tolerance, independence, quality of life and survival.
The researchers examined health records from 52,236 people with different cancers. About 73 percent of people in the pancreatic adenocarcinoma study group met the study's weight-loss criteria at some point during their illness.
That figure needs context. It does not mean that 73 percent of people are severely cachectic on the day they are diagnosed. The researchers assessed weight change over time using records that could begin before diagnosis and continue during follow-up. The study nevertheless showed that weight loss can begin early and that people with pancreatic cancer face a particularly high risk.
The researchers also identified patterns involving age, sex, ancestry, other health conditions and the amount and timing of weight loss. Some findings suggested possible biological differences in how cachexia develops.
The researchers did not develop prediction models specifically for pancreatic cancer. Their findings should not be treated as a tool that can predict an individual patient's course.
Read the cachexia atlas in Nature Medicine
The study expands a preprint first posted in September 2025:
What this means for patients and caregivers
Cancer cachexia should not be dismissed as an unavoidable side effect that only deserves attention near the end of illness.
Unintentional weight loss should be raised with the cancer team even when it seems modest. Patients and caregivers can ask:
- Is this weight loss likely to be cachexia?
- Can I be referred to a dietitian with cancer experience?
- Should muscle loss, strength and physical function be assessed?
- Could pain, nausea, pancreatic enzyme problems, diabetes or difficulty eating be contributing?
- Are there nutrition, exercise or supportive-care programs available?
- Is there a clinical study for cachexia or muscle loss?
Early documentation matters. A recorded pattern of weight and muscle loss may make it easier to obtain support than waiting until the loss becomes severe.
B.C. clarified genetic testing and faster investigation of symptoms
BC Cancer's updated Upper Gastrointestinal Cancers guidance came into effect in October.
The update says British Columbia should offer hereditary genetic testing to everyone diagnosed with pancreatic cancer or a pancreatic neuroendocrine tumour.
That matters for two reasons. First, an inherited gene change may affect treatment decisions. Second, it can provide information for relatives who may also carry the change and need their own risk assessment.
The guidance also says eligible health-care providers who do not specialize in genetics can arrange the testing in B.C. That could reduce delays where patients would otherwise wait for a separate genetics referral before testing begins.
Other important points in the update include:
- Suspected pancreatic cancer should be investigated promptly.
- Jaundice — yellowing of the skin or eyes — in a person over 40 requires urgent assessment.
- Imaging and blood work should not delay referral when pancreatic cancer is suspected.
- There is no recommended routine screening program for people at average risk.
- Assessment and treatment planning should involve a multidisciplinary team.
Read BC Cancer's Upper Gastrointestinal Cancers guidance (PDF)
What this means for patients
The B.C. guidance applies to British Columbia. It does not automatically create the same pathway in other provinces or territories.
However, patients elsewhere in Canada can still ask whether hereditary testing is available to them and whether a result could affect their treatment or their family's care.
Useful questions include:
- Should I receive hereditary genetic testing?
- Who can order it?
- Will tumour testing also be performed?
- How will my relatives be informed if an inherited change is found?
- Will the result affect treatment or clinical-trial eligibility?
The guidance's October effective date also needs care. It shows that B.C. has clarified its current approach. The document alone does not prove that every part of the pathway began in October or that every patient will experience the pathway in the same way.
New national evidence on Canada's pancreatic cancer systems
In October, The Heather Cutler Foundation published Where You Live Matters: How Canada Responds to Pancreatic Cancer.
The report was researched and written through Policy Builders of Tomorrow, the foundation's student research program. Eight Memorial University student researchers examined the policies, programs and evidence available across Canada's provinces and territories.
The underlying research was conducted from June to August 2025. The report assessed topics including provincial cancer strategies, biomarker and genetic testing, drug coverage, clinical trials, timely care, travel support, navigation and research funding.
Some jurisdictions were not given overall grades because the publicly available evidence was insufficient. That matters: an absence of usable public evidence is itself important when patients and governments need to understand how a system is performing.
Read Where You Live Matters: How Canada Responds to Pancreatic Cancer
Why the report matters
October's individual research stories involved vaccines, tumour biology, weight loss and genetic testing. The report asks a different question: once a discovery exists, is the Canadian health system organized to deliver testing, treatment, trials and support fairly?
That system question connects directly to the daraxonrasib story. Scientific progress has limited value to patients if a medicine is not approved, funded, available through a trial or realistically obtainable in the province where they live.
For patients and families: what to take from October
October's stories did not produce a new standard treatment for pancreatic cancer in Canada. They did produce several useful actions and questions.
Conversations to have now
- Ask whether hereditary genetic testing is appropriate.
- Report unintentional weight loss early.
- Ask about dietitian and supportive-care referrals.
- Ask whether a clinical trial may be appropriate.
- Ask how a new treatment reported in the news can actually be accessed in Canada.
Research to watch
- Whether KRAS-directed vaccines are tested in a phase 3 study designed to measure recurrence and survival.
- Whether approaches based on MYC or tumour heterogeneity can be translated from laboratory models into treatments.
- Whether cachexia research leads to earlier identification and effective interventions.
- Whether other provinces adopt clearer hereditary-testing pathways for pancreatic cancer.
- Whether daraxonrasib moves toward Canadian approval or another realistic access route.
Read September's edition: All the Advances in Pancreatic Cancer This Month.
If you are looking for support or information, The Heather Cutler Foundation's website brings together resources for Canadians living with pancreatic cancer and the people who care for them. If you have a question about a story in this roundup or an access issue affecting your family, please contact the foundation.
The information in this article is general information about research and health policy. It is not medical advice and does not replace advice from your own cancer-care team.
